Clinical trial
Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic…
NCT00003797 · Brown University, Other · Unknown status
Key facts
| NCT number | NCT00003797 |
|---|---|
| Title | Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas |
| Official title | Herceptin (NSC #688097) and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/NEU |
| Lead sponsor | Brown University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, gemcitabine hydrochloride |
| Enrollment | 41 |
| Start date | Mar 1, 1999 |
| First posted | May 2, 2003 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: